<DOC>
	<DOCNO>NCT00151242</DOCNO>
	<brief_summary>This trial study all-trans retinoic acid combination induction consolidation therapy well pegfilgrastim consolidation therapy young patient newly diagnose acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Study All-Trans Retinoic Acid , Induction Consolidation Therapy , Pegfilgrastim After Consolidation Therapy Younger Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>First Induction Therapy : - Cytarabine 100 mg/m² cont . i.v . day 1-7 - Idarubicin 12 mg/m² i.v . day 1,3,5 - Etoposide 100 mg/m² i.v . day 1-3 - ± ATRA 45 mg/m² p.o . day 6-8 - ATRA 15 mg/m² p.o . day 9-21 Second Induction Therapy : - Cytarabine 100 mg/m² cont . i.v . day 1-7 - Idarubicin 12 mg/m² i.v . day 1 3 - Etoposide 100 mg/m² i.v . day 1-3 - ± ATRA 45 mg/m² p.o . day 6-8 - ATRA 15 mg/m² p.o . day 9-21 Consolidation Therapy : cohort 1 ( &lt; = ID 336 ) - Cytarabine 3 g/m² 2x/die i.v . Tag 1,3,5 - ± ATRA 15 mg/m² p.o . Tag 6-21 - Pegfilgrastim 6 mg s.c day 10 cohort 2 ( &gt; ID 336 ) - Cytarabine 3 g/m² 2x/die i.v . Tag 1,2,3 - ± ATRA 15 mg/m² p.o . Tag 4-21 - Pegfilgrastim 6 mg s.c day 8</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Newly diagnose AML define accord World Health Organization ( WHO ) classification ( exclude acute promyelocytic leukemia [ APL ] ) Ages 1860 year Written inform consent patient study entry . Molecular cytogenetical diagnostics initial bone marrow peripheral blood specimen central reference laboratory Bleeding independent AML Acute promyelocytic leukemia Uncontrollable infection Participation concurrent clinical study Insufficiency kidney ( creatinine &gt; 1.5x upper normal serum level ) , liver ( bilirubin , AST AP &gt; 2x upper normal serum level ) , severe obstructive restrictive ventilation disorder , heart failure New York Heart Association ( NYHA ) III/IV Severe neurological psychiatric disorder interfere ability give inform consent . No consent registration , storage process individual diseasecharacteristics course . Performance status WHO &gt; 2 Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>